A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Phase 2

Recruiting

• Conditions: Hepatocellular Carcinoma
• Interventions: Drug: Tislelizumab + Sitravatinib

• Registration Number: NCT05407519
• Lead Sponsor: Anhui Provincial Hospital

Brief Summary

This is an open label, multi-center, single arm study to evaluate the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative resection.

Detailed Description

Hepatocellular carcinoma (HCC) is a malignant tumor with high morbidity and mortality. Surgical resection is the most important radical treatment. However, the recurrence rate is high especially in the patients with high risk of recurrence after curative resection. How to reduce postoperative recurrence and improve survival is currently a direction that is worth exploring.

Until now there is no standard postoperative adjuvant therapy. Various adjuvant treatment methods including immunotherapy, targeted therapy, TACE are being studied. This study is to explore the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in HCC patients who are at high risk of recurrence after curative resection.

Study Timeline

• Study First Submitted: 2022-05-30
• Study First Submitted QC: 2022-06-02
• Study First Posted: 2022-06-07
• Study Start: 2022-07-25
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-20
• Last Update Posted: 2023-03-22
• Primary Completion: 2026-06-30
• Study Completion: 2026-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Subjects with a histopathological or cytologically diagnosis of HCC
2. Subjects who have undergone a curative resection
3. High risk for HCC recurrence as protocol defined
4. No previous systematic treatment and locoregional therapy for HCC
5. Child-Pugh Score, Class A
6. ECOG performance status 0 or 1
7. Full recovery from surgical resection
8. Adequate organ function
9. Absence of major macrovascular invasion
10. No extrahepatic spread
11. Life expectancy of at least 6 months

Exclusion Criteria

1. Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC
2. Evidence of residual, recurrent, or metastatic disease
3. Known history of serious allergy to any component of tislelizumab or sitravatinib preparations
4. History of hepatic encephalopathy
5. Tumor thrombus in portal vein or superior mesenteric vein or inferior caval vein
6. Portal hypertension with bleeding esophageal or gastric varices within 6 months prior to initiation of treatment
7. Any bleeding or thrombotic disorder within 6 months prior to initiation of treatment
8. Any active malignancy within 2 years prior to the start of treatment
9. Active or history of autoimmune disease
10. Other acute or chronic conditions, psychiatric disorders, or laboratory abnormalities that may increase the risk of study participation
11. Pregnant or lactating women

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Tislelizumab 200mg IV q3w + Sitravatinib 100mg PO qd	Tislelizumab + Sitravatinib	Tislelizumab 200mg IV q3w + Sitravatinib 100mg PO qd Tislelizumab and Sitravatinib will be administered until the disease recurrence, intolerable toxicity, death, withdrawal of consent or completion of 17 cycles of Tislelizumab.

Primary Outcome Measures

Name	Time	Method
RFS rate	Observation period 24 months	2-year Recurrence Free Survival Rate (2-year RFS rate) \[Time Frame: Observation period 24 months\] 2-year RFS rate is defined as the proportion of patients alive and free of recurrence at 2 years after curative resection.

Secondary Outcome Measures

Name	Time	Method
TTR	24 months	1.Time to recurrence (TTR) \[Time Frame: 24 months\] TTR is defined as the time from the date of curative resection to the first documented recurrence.
RFS	24 months	2.Recurrence-Free Survival (RFS) \[Time Frame: 24 months\] RFS is defined as the time from the date of curative resection to the first documented recurrenceor death due to any cause, whichever occurs first.
RFS rate	12 months	3.1-year RFS rate \[Time Frame: 12 months\]; 1-year RFS rate is defined as the proportion of patients alive and free of recurrence at 1 yearsafter curative resection.
OS	24 months	4.Overall Survival (OS）\[Time Frame: 24 months\] OS is defined as the time from the date of curative resection until death due to any cause.
OS rate	12 months/24 months	5.1-year OS rate/2-year OS rate \[Time Frame: 12 months/24 months\] OS rate is defined as the proportion of patients who have not experienced death from any causeat 12 and 24 months after curative resection.
AEs	24 months	6.Adverse Events (AEs) \[ Time Frame: 24 months \] The grade of AEs and the number of patients with AEs are assessed based on CTCAE v5.0

Trial Locations

Locations (1)

Anhui province hospital; 🇨🇳 Hefei, Anhui, China